30273-11-1

Basic information

• Product Name: 4-SEC-BUTYLANILINE
• Synonyms: 4-sec-butylbenzenamine;4-sec-Butylaniline;4-SEC-BUTYLANILINE;4-(2-BUTYL)ANILINE;AKOS BBS-00003701;4-(1-methylpropyl)-benzenamin;4-(1-methylpropyl)-Benzenamine;4-Amino-sec-butylbenzene
• CAS NO: 30273-11-1
• Molecular Formula: C₁₀H₁₅N
• Molecular Weight: 149.23
• EINECS: 250-108-9
• Mol File: 30273-11-1.mol
• Article Data: 3

Chemical Properties

• Melting Point: 1.08°C (estimate)
• Boiling Point: 244-245 °C727 mm Hg(lit.)
• Flash Point: 226 °F
• Appearance: /
• Density: 0.977 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.0308mmHg at 25°C
• Refractive Index: n20/D 1.537(lit.)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 5.02±0.10(Predicted)
• CAS DataBase Reference: 4-SEC-BUTYLANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-SEC-BUTYLANILINE(30273-11-1)
• EPA Substance Registry System: 4-SEC-BUTYLANILINE(30273-11-1)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• RIDADR: 2810
• WGK Germany: 3
• HazardClass: IRRITANT
• PackingGroup: III
• Hazardous Substances Data: 30273-11-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-SEC-BUTYLANILINE is used as a reagent in the preparation of [dimethyl(dioxo)purinyl]alkanecarboxamides. These compounds serve as multifunctional TRPA1 antagonists and PDE4/7 inhibitors, which have potential therapeutic applications in the treatment of various types of pain. By targeting these specific receptors and enzymes, 4-SEC-BUTYLANILINE plays a crucial role in the development of novel pain management medications.

InChI:InChI=1/C10H15N/c1-3-8(2)9-4-6-10(11)7-5-9/h4-8H,3,11H2,1-2H3

Upstream product

• 30273-11-1 4-sec-butylaniline 
• 513-48-4 2-butyl iodide 
• 540-37-4 p-aminoiodobenzene 
• 92100-30-6 p-nitro-sec-butylbenzene 
• 135-98-8 sec-Butylbenzene 
• 4237-40-5 1-(iso-propyl)-4-nitrobenzene 
• 62-53-3 aniline 
• 78-92-2 iso-butanol 
• 5435-44-9 (E)-3-Ureido-but-2-enoic acid ethyl ester 

Downstream Products

• 135-98-8 sec-Butylbenzene 
• 88329-16-2 4-(sec-butyl)-N,N-dimethylaniline 
• 30273-11-1 (+)-4-sec-butyl-aniline 
• 30273-11-1 (-)-4-sec-butyl-aniline 
• 71758-09-3 4-sec-Butyl-2,6-diethyl-phenylamine 
• 175353-99-8 N-((tert-butyloxy)carbonyl)-N'-(n-butyl)-N''-(4-sec-butylphenyl)iminodiacetic acid diamide 
• 175353-93-2 [(4-sec-Butyl-phenylcarbamoyl)-methyl]-cyclohexylcarbamoylmethyl-carbamic acid tert-butyl ester 
• 480439-26-7 4-sec-butylphenyl isocyanate 
• 349121-01-3 2-bromo-N-(4-sec-butyl-phenyl)-acetamide 
• 948889-68-7 C₁₈H₂₁NO₂ 
• 287976-94-7 4-(3-methylpropyl)-N,N-bis(4-bromophenyl)aniline 
• 1268258-80-5 N-[(1-methyl-1H-pyrazole-4-yl)carbonyl]-N'-(4-(sec-butyl)phenyl)thiourea 

Relevant articles and documents

Nickel-catalyzed Negishi cross-coupling reactions of secondary alkylzinc halides and aryl iodides

A general Ni-catalyzed process for the cross-coupling of secondary alkylzinc halides and aryl/heteroaryl iodides has been developed. This is the first process to overcome the isomerization and β-hydride elimination problems that are associated with the use of secondary nucleophiles, and that have limited the analogous Pd-catalyzed systems. The impact of salt additives was also investigated. It was found that the presence of LiBF4 dramatically improves both isomeric retention and yield for challenging substrates.(Figure Presented)

Synthesis and evaluation of 4-alkylanilines as mammary tumor inhibiting aromatase inhibitors

The 4-alkylanilines 1-20 were synthesized to elucidate the importance of the glutarimide moiety for the aromatase inhibiting activity of aminoglutethimide [3-(4-aminophenyl)-3-ethylpiperidine-2,6-dione, AG], the only non-steroidal aromatase inhibitor which is commercially available at present. The most interesting compounds were the (4-aminophenyl)cycloalkanes 4-6 (4, c-pentyl; 5, c-hexyl; 6, c-heptyl) and the 1-alkyl-1-(4-aminophenyl)cyclohexanes 1-3 (1, CH3; 2, C2H5; 3, n-C3H7). Derivatives 1-6 are stronger inhibitors of human placental aromatase than AG exhibiting relative potencies from 1.5 to 2.7 (AG≡1). For selectivity of action, the inhibition of desmolase (cholesterol side chain cleavage enzyme) was determined. Compounds 1-3 showed an inhibition comparable to AG, whereas compounds 4-6 exhibited no effect on desmolase. Being more potent and selective aromatase inhibitors in vitro, compounds 4-6, however, were not superior to AG in vivo, when the reduction of plasma estradiol concentration and the tumor inhibiting activity (PMSG-primed SD rats and DMBA-induced mammary carcinoma of the SD rat, postmenopausal model) were concerned.

9-(P-phenylazoanilino)-7-methyl-1H-imidazo[4,5-f]quinolines

A series of 9-(substituted amino)imidazo[4,5-f]quinolines are effective anthelmintic agents; particularly in respect to the tapeworm Hymenolepis nana.